Breakthrough Business Models Drug Development for Rare and Neglected Diseases and Individualized Therapies: Workshop Summary (2009) / Chapter Skim
Currently Skimming:
Appendix B: Speaker Biographies
Appendix B: Speaker Biographies
Pages 113-127
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 113... ...
Project activities included a Diffusion of Effective Behavioral Interventions (DEBI) project, which provided curriculum development and training on eight proven effective HIV prevention interventions; an anti-HIV/AIDS stigma project; an annual health summit for community health agencies; and more than 20 other CDC task order projects.
|
From page 114... ...
She serves on the board and executive committee of the Research Triangle Park Foundation, on the board of the National Institute for Statistical Sciences, on the board of the Northeast Biodefense Center and the New England Center of Excellence in Biodefense and Emerging Infectious Diseases, and on the council of the National Institute of Child Health and Human Development. Prior to being named President of the Burroughs Wellcome Fund in 1994,
|
From page 115... ...
(member, IOM Forum on Drug Discovery, Development, and Translation) , is Director and Chief Executive Officer and Chief Operating Officer of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM)
|
From page 116... ...
(Co-chair, IOM Forum on Drug Discovery, Development, and Translation) , is currently Vice President, Scientific Affairs, and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly and Company, Indianapolis, Indiana.
|
From page 117... ...
in January 2007, where he was Senior Vice President for Science and Technology with strategic responsibility for advancing the company's human health business through licensing and business development, science, technology, and medical outreach and advocacy, including global medical professional relations and science policy. In 2002 and 2003, he also headed worldwide pharmaceutical research and development for Pfizer.
|
From page 118... ...
(member, IOM Forum on Drug Discovery, Development, and Translation) , is Director, Office of Rare Diseases, at NIH.
|
From page 119... ...
As Director of NIH's Office of Rare Diseases, he has devoted particular attention to efforts to stimulate research on these diseases and develop information for the rare disease community. The office has cosponsored approximately 725 scientific workshops and symposia with the NIH Research Institutes and Centers and patient support groups.
|
From page 120... ...
In that position, she developed and oversaw an $8 million translational research program aimed at increasing industry participation in drug development for rare diseases. She has been involved in the planning of several meetings to identify and remove barriers to therapy development for neuromuscular diseases and serves on numerous advisory boards, including the Department of Health and Human Services' Federal Advisory Committee for muscular dystrophy.
|
From page 121... ...
Meeker, M.D., is Executive Vice President, Therapeutics, Bio surgery and Transplant, at Genzyme. He joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program.
|
From page 122... ...
In addition to managing the intellectual property portfolio of NIAID and promoting the development and commercialization of NIAID's inventions, OTD is responsible for negotiating and managing transactional agreements, including Material Transfer Agreements, Cooperative Research and Development Agreements, and other collaboration agreements that enable NIAID to execute successful and effective research and R&D programs around the world. He and his staff have negotiated a wide variety of agreements with NIAID partners, which include universities, nongovernmental organizations, other U.S.
|
From page 123... ...
She is actively involved in working within FDA and with industry, patient groups, and other stakeholders for the development of drugs and biologic products for rare diseases, and her work focuses on regulatory decisions and policy affecting the clinical development and approval of these products. Anne Quinn Young, M.P.H., is Program Director at the Multiple Myeloma Research Foundation (MMRF)
|
From page 124... ...
Ms. Quinn Young previously worked in health care public relations at Burson-Marsteller and Chandler Chicco Agency, where she developed disease awareness campaigns for a number of disorders following a postgraduate internship at the Department of Justice, Antitrust Division.
|
From page 125... ...
from Princeton University as a Woodrow Wilson Scholar and completed a fellowship in the Robert Wood Johnson Clinical Scholars Program at the University of California at San Francisco/Stanford. He presently serves on the Board of Directors for Community Catalyst, a U.S.-based national advocacy organization working to ensure quality affordable health care for all; sits on the Advisory Board for TropIKA, a new web-based research and policy portal from the Special Programme for Research and Training in Tropical Diseases (TDR)
|
From page 126... ...
Dr. Sung is Founding Chair of the Health Research Alliance, a growing consortium of private foundations and voluntary health agencies with a shared interest in fostering basic science discoveries and removing barriers that prevent those discoveries from being translated into clinical studies and then into better health.
|
From page 127... ...
Wetmore has had a successful career managing complex multidisciplinary drug discovery projects and teams. She obtained her Ph.D.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.